Informing antiviral effectiveness for influenza A and SARS-CoV-2 by quantifying within-host interaction between transmission and immunity Article Swipe
Deven V. Gokhale
,
Miriã F. Criado
,
Dawne K. Rowe
,
Sandra M. Tomkins
,
Pejman Rohani
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1101/2025.03.11.642706
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1101/2025.03.11.642706
Antiviral therapies are among the most effective pharmaceutical interventions in treatment of a variety of viral pathogens. To optimize the antiviral effectiveness it is crucial to characterize the relationship between multiple cellular modes of antiviral action and the complex response of the host’s innate immune system relative to the within host dynamics of a proliferating virus. Since their introduction in 1968 and 2019, Influenza A virus (IAV) H3N2 and Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), respectively, have caused unprecedented damage on the public health infrastructure globally. In addition to the substantial burden of morbidity and mortality around the world, both viruses have the potential of undergoing evolution leading to antigenic escape from the prevailing interventions. These biological characteristics advocate for urgent development of effective antivirals for the treatment of IAV and SARS-CoV-2. In this multi-stage study, we develop a suite of within-host models encompassing a number of hypotheses regarding virus-specific innate host functional responses and their impacts on the proliferation of IAV H3N2 and SARS-CoV-2 viruses. We use likelihood-based statistical inference to confront these hypotheses with infection data on IAV H3N2 and SARS-CoV-2 from infection experiments in ferrets. Upon identifying the best-fitting model of within-host dynamics, we can quantify the potential impact of antiviral drug therapy as a function of effectiveness and timing of initiation. We find significant mechanistic differences between the infection dynamics of H3N2 IAV and SARS-CoV-2 and associated model parameters. The treatment consequences of these differences are that SARS-CoV-2 is harder to control with antivirals, requiring earlier initiation and a more effective drug. Author summary Antiviral drugs are prophylactic chemical agents that are used to contain several viral infections. Influenza A H3N2 virus (H3N2) and Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) are very important viral pathogens that have caused unprecedented, global public health damage in the recent times. This makes development of antiviral drugs crucial along with other pharmaceutical prophylactics like vaccination. To optimize the pathogen specific effectiveness, however, it is necessary to simultaneously explore the relationship among the intra-host viral kinetics, immune dynamics and modes of antiviral action. In this article we theoretically analyze antiviral action of a drug in union with effect of the host’s innate immune system in containing infections of SARS-CoV-2 and H3N2 in infection experiments with ferrets. We find fundamental differences in the requisite antiviral effectiveness which, we posit, is due to substantially different inter-cellular proliferation potential between the two viruses.
Related Topics
Concepts
Host (biology)
Transmission (telecommunications)
Virology
Immunity
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Coronavirus disease 2019 (COVID-19)
Biology
2019-20 coronavirus outbreak
Immunology
Medicine
Computer science
Immune system
Genetics
Telecommunications
Infectious disease (medical specialty)
Disease
Internal medicine
Outbreak
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1101/2025.03.11.642706
- https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdf
- OA Status
- green
- References
- 52
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4408404433
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4408404433Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1101/2025.03.11.642706Digital Object Identifier
- Title
-
Informing antiviral effectiveness for influenza A and SARS-CoV-2 by quantifying within-host interaction between transmission and immunityWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-03-12Full publication date if available
- Authors
-
Deven V. Gokhale, Miriã F. Criado, Dawne K. Rowe, Sandra M. Tomkins, Pejman RohaniList of authors in order
- Landing page
-
https://doi.org/10.1101/2025.03.11.642706Publisher landing page
- PDF URL
-
https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdfDirect OA link when available
- Concepts
-
Host (biology), Transmission (telecommunications), Virology, Immunity, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), Biology, 2019-20 coronavirus outbreak, Immunology, Medicine, Computer science, Immune system, Genetics, Telecommunications, Infectious disease (medical specialty), Disease, Internal medicine, OutbreakTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
52Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4408404433 |
|---|---|
| doi | https://doi.org/10.1101/2025.03.11.642706 |
| ids.doi | https://doi.org/10.1101/2025.03.11.642706 |
| ids.openalex | https://openalex.org/W4408404433 |
| fwci | 0.0 |
| type | preprint |
| title | Informing antiviral effectiveness for influenza A and SARS-CoV-2 by quantifying within-host interaction between transmission and immunity |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10167 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9878000020980835 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Influenza Virus Research Studies |
| topics[1].id | https://openalex.org/T10118 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9771999716758728 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2725 |
| topics[1].subfield.display_name | Infectious Diseases |
| topics[1].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[2].id | https://openalex.org/T11243 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9542999863624573 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Respiratory viral infections research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C126831891 |
| concepts[0].level | 2 |
| concepts[0].score | 0.709941029548645 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q221673 |
| concepts[0].display_name | Host (biology) |
| concepts[1].id | https://openalex.org/C761482 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6853646636009216 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q118093 |
| concepts[1].display_name | Transmission (telecommunications) |
| concepts[2].id | https://openalex.org/C159047783 |
| concepts[2].level | 1 |
| concepts[2].score | 0.659984290599823 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[2].display_name | Virology |
| concepts[3].id | https://openalex.org/C2779341262 |
| concepts[3].level | 3 |
| concepts[3].score | 0.598300039768219 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q182581 |
| concepts[3].display_name | Immunity |
| concepts[4].id | https://openalex.org/C3007834351 |
| concepts[4].level | 5 |
| concepts[4].score | 0.5399423241615295 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q82069695 |
| concepts[4].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| concepts[5].id | https://openalex.org/C3008058167 |
| concepts[5].level | 4 |
| concepts[5].score | 0.5290709137916565 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[5].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[6].id | https://openalex.org/C86803240 |
| concepts[6].level | 0 |
| concepts[6].score | 0.4349651634693146 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[6].display_name | Biology |
| concepts[7].id | https://openalex.org/C3006700255 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4157017469406128 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q81068910 |
| concepts[7].display_name | 2019-20 coronavirus outbreak |
| concepts[8].id | https://openalex.org/C203014093 |
| concepts[8].level | 1 |
| concepts[8].score | 0.32138949632644653 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[8].display_name | Immunology |
| concepts[9].id | https://openalex.org/C71924100 |
| concepts[9].level | 0 |
| concepts[9].score | 0.3045443892478943 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[9].display_name | Medicine |
| concepts[10].id | https://openalex.org/C41008148 |
| concepts[10].level | 0 |
| concepts[10].score | 0.2605733573436737 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[10].display_name | Computer science |
| concepts[11].id | https://openalex.org/C8891405 |
| concepts[11].level | 2 |
| concepts[11].score | 0.23591646552085876 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[11].display_name | Immune system |
| concepts[12].id | https://openalex.org/C54355233 |
| concepts[12].level | 1 |
| concepts[12].score | 0.1251389980316162 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[12].display_name | Genetics |
| concepts[13].id | https://openalex.org/C76155785 |
| concepts[13].level | 1 |
| concepts[13].score | 0.09563007950782776 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q418 |
| concepts[13].display_name | Telecommunications |
| concepts[14].id | https://openalex.org/C524204448 |
| concepts[14].level | 3 |
| concepts[14].score | 0.08988499641418457 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[14].display_name | Infectious disease (medical specialty) |
| concepts[15].id | https://openalex.org/C2779134260 |
| concepts[15].level | 2 |
| concepts[15].score | 0.07525578141212463 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[15].display_name | Disease |
| concepts[16].id | https://openalex.org/C126322002 |
| concepts[16].level | 1 |
| concepts[16].score | 0.06394922733306885 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[16].display_name | Internal medicine |
| concepts[17].id | https://openalex.org/C116675565 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q3241045 |
| concepts[17].display_name | Outbreak |
| keywords[0].id | https://openalex.org/keywords/host |
| keywords[0].score | 0.709941029548645 |
| keywords[0].display_name | Host (biology) |
| keywords[1].id | https://openalex.org/keywords/transmission |
| keywords[1].score | 0.6853646636009216 |
| keywords[1].display_name | Transmission (telecommunications) |
| keywords[2].id | https://openalex.org/keywords/virology |
| keywords[2].score | 0.659984290599823 |
| keywords[2].display_name | Virology |
| keywords[3].id | https://openalex.org/keywords/immunity |
| keywords[3].score | 0.598300039768219 |
| keywords[3].display_name | Immunity |
| keywords[4].id | https://openalex.org/keywords/severe-acute-respiratory-syndrome-coronavirus-2 |
| keywords[4].score | 0.5399423241615295 |
| keywords[4].display_name | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| keywords[5].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[5].score | 0.5290709137916565 |
| keywords[5].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[6].id | https://openalex.org/keywords/biology |
| keywords[6].score | 0.4349651634693146 |
| keywords[6].display_name | Biology |
| keywords[7].id | https://openalex.org/keywords/2019-20-coronavirus-outbreak |
| keywords[7].score | 0.4157017469406128 |
| keywords[7].display_name | 2019-20 coronavirus outbreak |
| keywords[8].id | https://openalex.org/keywords/immunology |
| keywords[8].score | 0.32138949632644653 |
| keywords[8].display_name | Immunology |
| keywords[9].id | https://openalex.org/keywords/medicine |
| keywords[9].score | 0.3045443892478943 |
| keywords[9].display_name | Medicine |
| keywords[10].id | https://openalex.org/keywords/computer-science |
| keywords[10].score | 0.2605733573436737 |
| keywords[10].display_name | Computer science |
| keywords[11].id | https://openalex.org/keywords/immune-system |
| keywords[11].score | 0.23591646552085876 |
| keywords[11].display_name | Immune system |
| keywords[12].id | https://openalex.org/keywords/genetics |
| keywords[12].score | 0.1251389980316162 |
| keywords[12].display_name | Genetics |
| keywords[13].id | https://openalex.org/keywords/telecommunications |
| keywords[13].score | 0.09563007950782776 |
| keywords[13].display_name | Telecommunications |
| keywords[14].id | https://openalex.org/keywords/infectious-disease |
| keywords[14].score | 0.08988499641418457 |
| keywords[14].display_name | Infectious disease (medical specialty) |
| keywords[15].id | https://openalex.org/keywords/disease |
| keywords[15].score | 0.07525578141212463 |
| keywords[15].display_name | Disease |
| keywords[16].id | https://openalex.org/keywords/internal-medicine |
| keywords[16].score | 0.06394922733306885 |
| keywords[16].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.1101/2025.03.11.642706 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306402567 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| locations[0].source.host_organization | https://openalex.org/I2750212522 |
| locations[0].source.host_organization_name | Cold Spring Harbor Laboratory |
| locations[0].source.host_organization_lineage | https://openalex.org/I2750212522 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1101/2025.03.11.642706 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5048216711 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9007-8914 |
| authorships[0].author.display_name | Deven V. Gokhale |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Deven Gokhale |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5022094216 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-0640-137X |
| authorships[1].author.display_name | Miriã F. Criado |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Miria Ferreira Criado |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5016501778 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4637-373X |
| authorships[2].author.display_name | Dawne K. Rowe |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Dawne K. Rowe |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5032233569 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Sandra M. Tomkins |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | S. Mark Tomkins |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5055282911 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7221-3801 |
| authorships[4].author.display_name | Pejman Rohani |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Pejman Rohani |
| authorships[4].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdf |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Informing antiviral effectiveness for influenza A and SARS-CoV-2 by quantifying within-host interaction between transmission and immunity |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10167 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9878000020980835 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Influenza Virus Research Studies |
| related_works | https://openalex.org/W3127156785, https://openalex.org/W3009669391, https://openalex.org/W4200329650, https://openalex.org/W4205215807, https://openalex.org/W3005417802, https://openalex.org/W4205754011, https://openalex.org/W4226296940, https://openalex.org/W3028835529, https://openalex.org/W3036314732, https://openalex.org/W3134376730 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1101/2025.03.11.642706 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306402567 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| best_oa_location.source.host_organization | https://openalex.org/I2750212522 |
| best_oa_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1101/2025.03.11.642706 |
| primary_location.id | doi:10.1101/2025.03.11.642706 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306402567 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | bioRxiv (Cold Spring Harbor Laboratory) |
| primary_location.source.host_organization | https://openalex.org/I2750212522 |
| primary_location.source.host_organization_name | Cold Spring Harbor Laboratory |
| primary_location.source.host_organization_lineage | https://openalex.org/I2750212522 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.biorxiv.org/content/biorxiv/early/2025/03/12/2025.03.11.642706.full.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1101/2025.03.11.642706 |
| publication_date | 2025-03-12 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3139167208, https://openalex.org/W2094966297, https://openalex.org/W286277626, https://openalex.org/W2156537900, https://openalex.org/W2218144341, https://openalex.org/W1508121266, https://openalex.org/W4211090574, https://openalex.org/W1520434148, https://openalex.org/W1995380235, https://openalex.org/W2060045092, https://openalex.org/W3164372712, https://openalex.org/W2884223232, https://openalex.org/W3144687672, https://openalex.org/W777202150, https://openalex.org/W3014989892, https://openalex.org/W3086329664, https://openalex.org/W3023366836, https://openalex.org/W3154308199, https://openalex.org/W1979158913, https://openalex.org/W2092500478, https://openalex.org/W3125227243, https://openalex.org/W3175396364, https://openalex.org/W2039082139, https://openalex.org/W2042492606, https://openalex.org/W3030537287, https://openalex.org/W3161424923, https://openalex.org/W2950049576, https://openalex.org/W2096372976, https://openalex.org/W2031913105, https://openalex.org/W2016430217, https://openalex.org/W2099019634, https://openalex.org/W2936804536, https://openalex.org/W1578831904, https://openalex.org/W2166022262, https://openalex.org/W2060735144, https://openalex.org/W2113797309, https://openalex.org/W2093625674, https://openalex.org/W2042925520, https://openalex.org/W2152803686, https://openalex.org/W2277437543, https://openalex.org/W2099929014, https://openalex.org/W2120865009, https://openalex.org/W2024700382, https://openalex.org/W2085862933, https://openalex.org/W2168573378, https://openalex.org/W2109977701, https://openalex.org/W2411447930, https://openalex.org/W3091654554, https://openalex.org/W2113105229, https://openalex.org/W2460362894, https://openalex.org/W1546736424, https://openalex.org/W2119131783 |
| referenced_works_count | 52 |
| abstract_inverted_index.A | 65, 274 |
| abstract_inverted_index.a | 13, 54, 139, 145, 208, 253, 353 |
| abstract_inverted_index.In | 87, 133, 344 |
| abstract_inverted_index.To | 18, 317 |
| abstract_inverted_index.We | 167, 216, 377 |
| abstract_inverted_index.as | 207 |
| abstract_inverted_index.in | 10, 60, 187, 299, 355, 365, 372, 381 |
| abstract_inverted_index.is | 24, 243, 325, 389 |
| abstract_inverted_index.it | 23, 324 |
| abstract_inverted_index.of | 12, 15, 34, 41, 53, 93, 105, 123, 129, 141, 147, 161, 194, 203, 210, 214, 225, 237, 306, 341, 352, 359, 368 |
| abstract_inverted_index.on | 81, 158, 179 |
| abstract_inverted_index.to | 26, 48, 89, 109, 172, 245, 268, 327, 391 |
| abstract_inverted_index.we | 137, 197, 347, 387 |
| abstract_inverted_index.IAV | 130, 162, 180, 227 |
| abstract_inverted_index.The | 234 |
| abstract_inverted_index.and | 37, 62, 69, 95, 131, 155, 164, 182, 212, 228, 230, 252, 278, 339, 370 |
| abstract_inverted_index.are | 3, 240, 261, 266, 286 |
| abstract_inverted_index.can | 198 |
| abstract_inverted_index.due | 390 |
| abstract_inverted_index.for | 120, 126 |
| abstract_inverted_index.the | 5, 20, 28, 38, 42, 49, 82, 90, 98, 103, 113, 127, 159, 191, 200, 222, 300, 319, 330, 333, 360, 382, 398 |
| abstract_inverted_index.two | 399 |
| abstract_inverted_index.use | 168 |
| abstract_inverted_index.1968 | 61 |
| abstract_inverted_index.H3N2 | 68, 163, 181, 226, 275, 371 |
| abstract_inverted_index.This | 303 |
| abstract_inverted_index.Upon | 189 |
| abstract_inverted_index.both | 100 |
| abstract_inverted_index.data | 178 |
| abstract_inverted_index.drug | 205, 354 |
| abstract_inverted_index.find | 217, 378 |
| abstract_inverted_index.from | 112, 184 |
| abstract_inverted_index.have | 77, 102, 292 |
| abstract_inverted_index.host | 51, 152 |
| abstract_inverted_index.like | 315 |
| abstract_inverted_index.more | 254 |
| abstract_inverted_index.most | 6 |
| abstract_inverted_index.that | 241, 265, 291 |
| abstract_inverted_index.this | 134, 345 |
| abstract_inverted_index.used | 267 |
| abstract_inverted_index.very | 287 |
| abstract_inverted_index.with | 176, 247, 311, 357, 375 |
| abstract_inverted_index.(IAV) | 67 |
| abstract_inverted_index.2019, | 63 |
| abstract_inverted_index.Acute | 71, 280 |
| abstract_inverted_index.Since | 57 |
| abstract_inverted_index.These | 116 |
| abstract_inverted_index.along | 310 |
| abstract_inverted_index.among | 4, 332 |
| abstract_inverted_index.drug. | 256 |
| abstract_inverted_index.drugs | 260, 308 |
| abstract_inverted_index.makes | 304 |
| abstract_inverted_index.model | 193, 232 |
| abstract_inverted_index.modes | 33, 340 |
| abstract_inverted_index.other | 312 |
| abstract_inverted_index.suite | 140 |
| abstract_inverted_index.their | 58, 156 |
| abstract_inverted_index.these | 174, 238 |
| abstract_inverted_index.union | 356 |
| abstract_inverted_index.viral | 16, 271, 289, 335 |
| abstract_inverted_index.virus | 66, 276 |
| abstract_inverted_index.(H3N2) | 277 |
| abstract_inverted_index.Author | 257 |
| abstract_inverted_index.Corona | 283 |
| abstract_inverted_index.Severe | 70, 279 |
| abstract_inverted_index.action | 36, 351 |
| abstract_inverted_index.agents | 264 |
| abstract_inverted_index.around | 97 |
| abstract_inverted_index.burden | 92 |
| abstract_inverted_index.caused | 78, 293 |
| abstract_inverted_index.damage | 80, 298 |
| abstract_inverted_index.effect | 358 |
| abstract_inverted_index.escape | 111 |
| abstract_inverted_index.global | 295 |
| abstract_inverted_index.harder | 244 |
| abstract_inverted_index.health | 84, 297 |
| abstract_inverted_index.immune | 45, 337, 363 |
| abstract_inverted_index.impact | 202 |
| abstract_inverted_index.innate | 44, 151, 362 |
| abstract_inverted_index.models | 143 |
| abstract_inverted_index.number | 146 |
| abstract_inverted_index.posit, | 388 |
| abstract_inverted_index.public | 83, 296 |
| abstract_inverted_index.recent | 301 |
| abstract_inverted_index.study, | 136 |
| abstract_inverted_index.system | 46, 364 |
| abstract_inverted_index.times. | 302 |
| abstract_inverted_index.timing | 213 |
| abstract_inverted_index.urgent | 121 |
| abstract_inverted_index.virus. | 56 |
| abstract_inverted_index.which, | 386 |
| abstract_inverted_index.within | 50 |
| abstract_inverted_index.world, | 99 |
| abstract_inverted_index.Virus-2 | 284 |
| abstract_inverted_index.action. | 343 |
| abstract_inverted_index.analyze | 349 |
| abstract_inverted_index.article | 346 |
| abstract_inverted_index.between | 30, 221, 397 |
| abstract_inverted_index.complex | 39 |
| abstract_inverted_index.contain | 269 |
| abstract_inverted_index.control | 246 |
| abstract_inverted_index.crucial | 25, 309 |
| abstract_inverted_index.develop | 138 |
| abstract_inverted_index.earlier | 250 |
| abstract_inverted_index.explore | 329 |
| abstract_inverted_index.impacts | 157 |
| abstract_inverted_index.leading | 108 |
| abstract_inverted_index.several | 270 |
| abstract_inverted_index.summary | 258 |
| abstract_inverted_index.therapy | 206 |
| abstract_inverted_index.variety | 14 |
| abstract_inverted_index.viruses | 101 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Syndrome | 73, 282 |
| abstract_inverted_index.addition | 88 |
| abstract_inverted_index.advocate | 119 |
| abstract_inverted_index.cellular | 32 |
| abstract_inverted_index.chemical | 263 |
| abstract_inverted_index.confront | 173 |
| abstract_inverted_index.dynamics | 52, 224, 338 |
| abstract_inverted_index.ferrets. | 188, 376 |
| abstract_inverted_index.function | 209 |
| abstract_inverted_index.host’s | 43, 361 |
| abstract_inverted_index.however, | 323 |
| abstract_inverted_index.multiple | 31 |
| abstract_inverted_index.optimize | 19, 318 |
| abstract_inverted_index.pathogen | 320 |
| abstract_inverted_index.quantify | 199 |
| abstract_inverted_index.relative | 47 |
| abstract_inverted_index.response | 40 |
| abstract_inverted_index.specific | 321 |
| abstract_inverted_index.viruses. | 166, 400 |
| abstract_inverted_index.Antiviral | 1, 259 |
| abstract_inverted_index.Influenza | 64, 273 |
| abstract_inverted_index.antigenic | 110 |
| abstract_inverted_index.antiviral | 21, 35, 204, 307, 342, 350, 384 |
| abstract_inverted_index.different | 393 |
| abstract_inverted_index.dynamics, | 196 |
| abstract_inverted_index.effective | 7, 124, 255 |
| abstract_inverted_index.evolution | 107 |
| abstract_inverted_index.globally. | 86 |
| abstract_inverted_index.important | 288 |
| abstract_inverted_index.infection | 177, 185, 223, 373 |
| abstract_inverted_index.inference | 171 |
| abstract_inverted_index.kinetics, | 336 |
| abstract_inverted_index.morbidity | 94 |
| abstract_inverted_index.mortality | 96 |
| abstract_inverted_index.necessary | 326 |
| abstract_inverted_index.pathogens | 290 |
| abstract_inverted_index.potential | 104, 201, 396 |
| abstract_inverted_index.regarding | 149 |
| abstract_inverted_index.requiring | 249 |
| abstract_inverted_index.requisite | 383 |
| abstract_inverted_index.responses | 154 |
| abstract_inverted_index.therapies | 2 |
| abstract_inverted_index.treatment | 11, 128, 235 |
| abstract_inverted_index.SARS-CoV-2 | 165, 183, 229, 242, 369 |
| abstract_inverted_index.antivirals | 125 |
| abstract_inverted_index.associated | 231 |
| abstract_inverted_index.biological | 117 |
| abstract_inverted_index.containing | 366 |
| abstract_inverted_index.functional | 153 |
| abstract_inverted_index.hypotheses | 148, 175 |
| abstract_inverted_index.infections | 367 |
| abstract_inverted_index.initiation | 251 |
| abstract_inverted_index.intra-host | 334 |
| abstract_inverted_index.pathogens. | 17 |
| abstract_inverted_index.prevailing | 114 |
| abstract_inverted_index.undergoing | 106 |
| abstract_inverted_index.Respiratory | 72, 281 |
| abstract_inverted_index.SARS-CoV-2. | 132 |
| abstract_inverted_index.antivirals, | 248 |
| abstract_inverted_index.development | 122, 305 |
| abstract_inverted_index.differences | 220, 239, 380 |
| abstract_inverted_index.experiments | 186, 374 |
| abstract_inverted_index.fundamental | 379 |
| abstract_inverted_index.identifying | 190 |
| abstract_inverted_index.infections. | 272 |
| abstract_inverted_index.initiation. | 215 |
| abstract_inverted_index.mechanistic | 219 |
| abstract_inverted_index.multi-stage | 135 |
| abstract_inverted_index.parameters. | 233 |
| abstract_inverted_index.significant | 218 |
| abstract_inverted_index.statistical | 170 |
| abstract_inverted_index.substantial | 91 |
| abstract_inverted_index.within-host | 142, 195 |
| abstract_inverted_index.(SARS-CoV-2) | 285 |
| abstract_inverted_index.best-fitting | 192 |
| abstract_inverted_index.characterize | 27 |
| abstract_inverted_index.consequences | 236 |
| abstract_inverted_index.encompassing | 144 |
| abstract_inverted_index.introduction | 59 |
| abstract_inverted_index.prophylactic | 262 |
| abstract_inverted_index.relationship | 29, 331 |
| abstract_inverted_index.vaccination. | 316 |
| abstract_inverted_index.(SARS-CoV-2), | 75 |
| abstract_inverted_index.Coronavirus-2 | 74 |
| abstract_inverted_index.effectiveness | 22, 211, 385 |
| abstract_inverted_index.interventions | 9 |
| abstract_inverted_index.proliferating | 55 |
| abstract_inverted_index.proliferation | 160, 395 |
| abstract_inverted_index.prophylactics | 314 |
| abstract_inverted_index.respectively, | 76 |
| abstract_inverted_index.substantially | 392 |
| abstract_inverted_index.theoretically | 348 |
| abstract_inverted_index.unprecedented | 79 |
| abstract_inverted_index.effectiveness, | 322 |
| abstract_inverted_index.infrastructure | 85 |
| abstract_inverted_index.inter-cellular | 394 |
| abstract_inverted_index.interventions. | 115 |
| abstract_inverted_index.pharmaceutical | 8, 313 |
| abstract_inverted_index.simultaneously | 328 |
| abstract_inverted_index.unprecedented, | 294 |
| abstract_inverted_index.virus-specific | 150 |
| abstract_inverted_index.characteristics | 118 |
| abstract_inverted_index.likelihood-based | 169 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 5 |
| citation_normalized_percentile.value | 0.10844682 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |